FR2832925B1 - Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation - Google Patents

Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation

Info

Publication number
FR2832925B1
FR2832925B1 FR0115601A FR0115601A FR2832925B1 FR 2832925 B1 FR2832925 B1 FR 2832925B1 FR 0115601 A FR0115601 A FR 0115601A FR 0115601 A FR0115601 A FR 0115601A FR 2832925 B1 FR2832925 B1 FR 2832925B1
Authority
FR
France
Prior art keywords
inflammation
oxobutanoic acid
treatment
acid derivatives
oxobutanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0115601A
Other languages
English (en)
Other versions
FR2832925A1 (fr
Inventor
Gerard Moinet
Dominique Marais
Philippe Maizeray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0115601A priority Critical patent/FR2832925B1/fr
Application filed by LIPHA SAS filed Critical LIPHA SAS
Priority to US10/497,491 priority patent/US7897644B2/en
Priority to PL02369845A priority patent/PL369845A1/xx
Priority to BR0214644-4A priority patent/BR0214644A/pt
Priority to KR1020047006346A priority patent/KR20050043728A/ko
Priority to HU0402242A priority patent/HUP0402242A3/hu
Priority to PCT/EP2002/012357 priority patent/WO2003047561A1/fr
Priority to AT02779532T priority patent/ATE355834T1/de
Priority to AU2002342883A priority patent/AU2002342883B2/en
Priority to DE60218726T priority patent/DE60218726T2/de
Priority to MXPA04005265A priority patent/MXPA04005265A/es
Priority to EP02779532A priority patent/EP1450780B1/fr
Priority to JP2003548817A priority patent/JP2005511654A/ja
Priority to RU2004120557/15A priority patent/RU2004120557A/ru
Priority to CA2468910A priority patent/CA2468910C/fr
Priority to ES02779532T priority patent/ES2280589T3/es
Priority to CNA028241045A priority patent/CN1599604A/zh
Priority to TW091134839A priority patent/TW200300670A/zh
Publication of FR2832925A1 publication Critical patent/FR2832925A1/fr
Priority to ZA200405246A priority patent/ZA200405246B/en
Publication of FR2832925B1 publication Critical patent/FR2832925B1/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0115601A 2001-12-03 2001-12-03 Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation Expired - Fee Related FR2832925B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR0115601A FR2832925B1 (fr) 2001-12-03 2001-12-03 Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
JP2003548817A JP2005511654A (ja) 2001-12-03 2002-11-06 炎症治療における４−オキソブタン酸誘導体の使用
EP02779532A EP1450780B1 (fr) 2001-12-03 2002-11-06 Utilisation de derives de l'acide 4-oxobutanoique pour le traitement d'inflammations
KR1020047006346A KR20050043728A (ko) 2001-12-03 2002-11-06 염증의 치료에서의 ４-옥소부타노산 유도체의 용도
HU0402242A HUP0402242A3 (en) 2001-12-03 2002-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
PCT/EP2002/012357 WO2003047561A1 (fr) 2001-12-03 2002-11-06 Utilisation de derives de l'acide 4-oxobutanoique pour le traitement d'inflammations
AT02779532T ATE355834T1 (de) 2001-12-03 2002-11-06 Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung
AU2002342883A AU2002342883B2 (en) 2001-12-03 2002-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
DE60218726T DE60218726T2 (de) 2001-12-03 2002-11-06 Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung
RU2004120557/15A RU2004120557A (ru) 2001-12-03 2002-11-06 Применение производных 4-оксомасляной кислоты для лечения воспаления
US10/497,491 US7897644B2 (en) 2001-12-03 2002-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
BR0214644-4A BR0214644A (pt) 2001-12-03 2002-11-06 Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação
MXPA04005265A MXPA04005265A (es) 2001-12-03 2002-11-06 Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion.
CA2468910A CA2468910C (fr) 2001-12-03 2002-11-06 Utilisation de derives de l'acide 4-oxobutanoique pour le traitement d'inflammations
ES02779532T ES2280589T3 (es) 2001-12-03 2002-11-06 Uso de derivados de acido 4-oxobutanoico en el tratamiento de la inflamacion.
CNA028241045A CN1599604A (zh) 2001-12-03 2002-11-06 4－氧代丁酸衍生物在治疗炎症中的用途
PL02369845A PL369845A1 (en) 2001-12-03 2002-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
TW091134839A TW200300670A (en) 2001-12-03 2002-11-29 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
ZA200405246A ZA200405246B (en) 2001-12-03 2004-07-01 Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0115601A FR2832925B1 (fr) 2001-12-03 2001-12-03 Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation

Publications (2)

Publication Number Publication Date
FR2832925A1 FR2832925A1 (fr) 2003-06-06
FR2832925B1 true FR2832925B1 (fr) 2006-07-14

Family

ID=8870049

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0115601A Expired - Fee Related FR2832925B1 (fr) 2001-12-03 2001-12-03 Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation

Country Status (19)

Country Link
US (1) US7897644B2 (fr)
EP (1) EP1450780B1 (fr)
JP (1) JP2005511654A (fr)
KR (1) KR20050043728A (fr)
CN (1) CN1599604A (fr)
AT (1) ATE355834T1 (fr)
AU (1) AU2002342883B2 (fr)
BR (1) BR0214644A (fr)
CA (1) CA2468910C (fr)
DE (1) DE60218726T2 (fr)
ES (1) ES2280589T3 (fr)
FR (1) FR2832925B1 (fr)
HU (1) HUP0402242A3 (fr)
MX (1) MXPA04005265A (fr)
PL (1) PL369845A1 (fr)
RU (1) RU2004120557A (fr)
TW (1) TW200300670A (fr)
WO (1) WO2003047561A1 (fr)
ZA (1) ZA200405246B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071161A1 (fr) 2007-12-03 2009-06-11 Merck Patent Gmbh Utilisation de dérivés de l'acide 4-oxobutanoïque dans le traitement de pathologies associées à des troubles immunologiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
JPS59144717A (ja) * 1983-02-07 1984-08-18 Microbial Chem Res Found 鎮痛剤
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
HRP970247B1 (en) * 1996-05-15 2002-02-28 Bayer Ag Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FR2777566B1 (fr) 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
US6060250A (en) * 1998-06-30 2000-05-09 Incyte Pharmaceuticals, Inc. Human transferases
AU4229499A (en) * 1998-07-30 2000-02-21 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
FR2793411B1 (fr) * 1999-05-11 2001-06-29 Synthelabo Utilisation de derives de l'acide succinique pour obtenir un medicament destine au traitement de l'inflammation
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients

Also Published As

Publication number Publication date
HUP0402242A3 (en) 2006-01-30
MXPA04005265A (es) 2004-10-11
JP2005511654A (ja) 2005-04-28
US7897644B2 (en) 2011-03-01
TW200300670A (en) 2003-06-16
DE60218726T2 (de) 2007-11-15
EP1450780B1 (fr) 2007-03-07
KR20050043728A (ko) 2005-05-11
RU2004120557A (ru) 2005-05-10
HUP0402242A2 (hu) 2005-02-28
AU2002342883B2 (en) 2007-11-29
ZA200405246B (en) 2005-06-24
ATE355834T1 (de) 2007-03-15
CA2468910A1 (fr) 2003-06-12
WO2003047561A1 (fr) 2003-06-12
EP1450780A1 (fr) 2004-09-01
FR2832925A1 (fr) 2003-06-06
CN1599604A (zh) 2005-03-23
BR0214644A (pt) 2004-11-03
PL369845A1 (en) 2005-05-02
US20050014768A1 (en) 2005-01-20
ES2280589T3 (es) 2007-09-16
DE60218726D1 (de) 2007-04-19
CA2468910C (fr) 2012-01-03
AU2002342883A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
TR200102072T2 (tr) İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
MA26901A1 (fr) Nouvelle composition pharmaceutique
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
NO20030411L (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
NO20010940L (no) TAN-1057 derivater
ATE458471T1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
FR2832925B1 (fr) Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE555787T1 (de) Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE241640T1 (de) Fusidinsäure-derivate
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
ITMI991653A0 (it) Uso della n-acetil-cisteina per la preparazione di composizioni farmac eutiche topiche per il trattamento di patologie allergiche delle vie r

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060831

CA Change of address
CD Change of name or company name
RN Application for restoration
IC Decision of the director general to declare irreceivable or to reject an appeal